Inside Neuland Lab's Peptide Facility | Pursuing 15–20% Growth On An Annual Basis Is Reasonable: Co
CNBC-TV18 · 23 Sept 2026 · 7 min
Management interview of Neuland Laboratories Ltd (NEULANDLAB), with 4 key numbers discussed.
- Saharsh Davuluri, CEO & MD, Neuland Laboratories Ltd
Neuland Labs considers 15-20% annual growth and a 25% EBITDA margin reasonable over the medium term, though quarterly performance will remain lumpy. The custom manufacturing solutions (CMS) segment now contributes over 60% of revenues, driven by 3-4 key commercial molecules. Management noted that client manufacturing campaigns are scheduled once or twice a year, causing occasional flat or de-growth quarters. Neuland is also exploring small, strategic capability-led acquisitions in the Western hemisphere, particularly the US.